Main Article Content


Aim:The aim of our study was to determine whether the ocular complications of onchocerciasis influenced the compliance with CDTI.


Materials and methods: We conducted a cross-sectional descriptive study including all subjects aged 10 years or more. . The variables studied were visual acuity, type of visual impairment, gender, onchocerciasis ocular manifestations, the number of time  Ivermectin was  taken over the last 5 years.


Results:We recruited 764 patients or 1528 eyes. The number of eyes with ocular manifestations of onchocerciasis was 56 while the number of eyes without was 1472. We found a prevalence of 48% good adherence CDTI within the general population. Nevertheless the prevalence among cases was of 57% good compliance compared to a prevalence of 48% among controls (P = 0.28). This similarity in the pattern of taking Ivermectin between female and male was found.



Patients with onchocerciasis ocular involvement showed better compliance to CDTI in the Littoral region. Gender is not a factor influencing compliance to CDTI in our study in contrast to some available reports in the literature. The pattern of taking Ivermectin is not a contributing factor predisposing male to onchocerciasis ocular involvement. In the absence of visual impairment, patients with onchocerciasis ocular involvement have better compliance to CDTI. : The presence of onchocerciasis ocular involvement seems to be a motivating factor to a better compliance to CDTI for affected patients.


Keywords: Compliance, Onchocerciasis, Ivermectin , Cameroon

Article Details

Author Biography

Emilienne Epee, FMBS

chargée de cours  département dophthalmologie ORL
How to Cite
Epee, E., Afetane, T. G., Aboutou, R., & Bella Assumpta, L. (2014). Lésions oculaires de l’onchocercose et observance au Traitement à L’Ivermectine Sous Directives Communautaires (TIDC). HEALTH SCIENCES AND DISEASE, 15(2). Retrieved from


  1. Références :
  2. - Don N Udall: Recent updates on Onchocerciasis: diagnosis and treatment. Clinical infectious diseases 2007, 44: 53 – 60.
  3. - World Health Organization: Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control. World Health Organ Tech Rep Ser 1995, 852:1-104.
  4. - Tekle et al.: Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasites & Vectors 2012, 5:28.
  5. - Gentilini M, Dufflo B : Les helminthiases: les filarioses in Médecine tropicale, AUPELF 2000.
  6. - Diawara L, Traore MO, Badji A, Bissan Y: Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009, 3:e497.
  7. - Afetane ETG: Epidémiologie des lésions oculaires de l’Onchocercose en zones TIDC du Littoral et de l’Ouest du Cameroun. Mémoire de fin de formation en vue de l’obtention du Diplôme de Spécialiste en Sciences Cliniques option Ophtalmologie. Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé 1, Yaoundé, 2013.
  8. - Stephen D, Mc Leod: Infectious keratitis in Ophthalmology 2nd Edition, Mosby, September 2003: 488 – 489.
  9. - IPSOR Medication Compliance and Persistence Special Interest Group: Standardizing definition of terms. International Society for Pharmacoeconomics and Outcomes Research 2005.
  10. - Yuan Y, L’italien G, Mukherjee J, Iloeje U: Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIVinfected patient cohort. HIV Med 2006, 7(3):156-62.
  11. - Iliyasu Z, Kabir M, Abubakar IS, Babashani M, Zubair ZA: Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Niger J Med 2005, 14(3):290-4.
  12. - Hopkins A : Recueillir des données pour lutter contre l’onchocercose. Revue de santé oculaire communautaire Janvier 2012, 9 (11): 13–14.
  13. - Brieger et al.: Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Parasites & Vectors 2011, 4:152.
  14. - Brieger WR, Otusanya SA, Oke GA, Oshiname FO, Adeniyi JD: Factors associated with coverage in community directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria. Trop Med and Int Health 2002, 7(1):11-18.
  15. - Maduka CU, Nweke LN, Miri ES, Amazigo U, Emukah EC, Richards FO: Missed treatment opportunities, for pregnant and breast-feeding women, in onchocerciasis mass-treatment programmes in south-eastern Nigeria. Ann Trop Med & Parasitol 2004, 98(7):697-702.

Most read articles by the same author(s)

1 2 > >>